Post-Op Immunotherapy May Lower Risk of Bladder Cancer Recurrence

A new study conducted by researchers from the Memorial Sloan Kettering Cancer Center has discovered that after undergoing bladder removal operations, the risk of high-grade bladder cancer recurrence decreased after the nivolumab formulation was administered to patients.

Together with a group of researchers, Dr. Dean Bajorin, who is a medical oncologist at the institute, evaluated more than 700 patients who had a high risk of urothelial cancer recurring after their kidney, ureter or bladder had been removed because of advanced metastatic bladder cancer.

Urothelial cancers are tumors that develop in the muscle lining of the urinary system. These cancers are usually referred to as bladder cancers as the majority of them begin in the bladder. Bladder cancer is an aggressive ailment, especially when it advances without treatment. Estimates show that in 2021, about 17,000 individuals will succumb to the ailment in the United States, with projections showing that in the next decade, these numbers will rise considerably.

During the study, 356 patients received a placebo immunotherapy formulation while the remaining 353 had nivolumab administered once every two weeks for a year to assess for any benefit accruing.

The researchers evaluated both quality of life and safety. The study reported that in comparison with high-risk patients who received the placebo, nivolumab decreased recurrence after a bladder removal operation. Additionally, in comparison to an estimated 11 months of disease-free survival from the patients in the placebo group, those from the nivolumab group had 21 months of disease-free survival.

The study’s corresponding author, Bajorin stated that study results as well as data was encouraging, explaining that new treatment options for muscle-invasive urothelial carcinoma were needed to enhance patient survival and disease control in the long term. The team’s findings, he said, could possibly change the standard of care for this fatal disease.

The researchers came to the conclusion that the data would need to be followed up and additional research carried out as it was not yet mature. Furthermore, Bajorin explained that the researchers’ phase 3 randomized trial showed that new therapies could be identified as being beneficial to patients when the research was carried out in a rigorous fashion. He added that the researchers were hopeful that, after the U.S. Food and Drug Administration  had reviewed the data, the agency would approve the treatment for use by patients who had high chances of the disease recurring,

Presently radiation therapy or surgery with chemotherapy are the standard treatments for various cancers, including lung cancer, breast cancer and leukemia.

The study was reported in the “New England Journal of Medicine.”

Patients can look forward to remedies that offer even better clinical outcomes given that a lot of companies, including Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF), are doing intensive research and development to make the treatment of bladder cancer more effective.

NOTE TO INVESTORS: The latest news and updates relating to Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.